IL-33 blockade attenuates vascular inflammation in a mouse model of Kawasaki disease vasculitis
The immune mechanisms underlying Kawasaki disease (KD), a febrile systemic vasculitis in children, are poorly understood. Reports indicate elevated levels of circulating IL-33 in acute KD patients; however, if IL-33 contributes to the pathogenesis of KD vasculitis remains unclear. Here, we used the Lactobacillus casei cell wall extract (LCWE)-induced murine model of KD to determine the contribution of IL-33 to vasculitis development. We observed increased expression of Il33 transcripts and IL-33 protein in LCWE-induced cardiovascular lesions. Bone marrow chimera experiments suggest that IL-33 production by both hematopoietic and stromal cells is important for LCWE-induced KD vasculitis; however, single-cell RNA sequencing, spatial transcriptomics, and flow cytometric analysis revealed that stromal cells were the predominant sources of IL-33. Furthermore, immune cells infiltrating LCWE-induced cardiovascular lesions expressed Il1rl1 transcripts, coding for the IL-33 receptor ST2. In vitro stimulation of bone marrow-derived macrophages with IL-33 enhanced their production of IL-1b and TNF-α. In vivo blockade of IL-33, using either neutralizing IL-33 antibody or Il33-/- mice, effectively attenuated LCWE-induced cardiovascular inflammation. Our results indicate that IL-33 contributes to LCWE-induced vascular inflammation through redundant mechanisms across multiple immune cell subsets rather than a single population and highlight IL-33 as a potential therapeutic target.
Authors
- Timothy R. Crother (ORCID: https://orcid.org/0000-0001-8465-6127)
- S. C. Chen
- B. Evan Ross
- Magali Noval Rivas (ORCID: https://orcid.org/0000-0001-5570-8928)
- R. Lee
- Prasant Kumar Jena (ORCID: https://orcid.org/0000-0002-6729-5881)
- Asli E. Atici (ORCID: https://orcid.org/0000-0003-1546-7191)
- Emily Aubuchon
- Waldiceu Verri Jr
- Thacyana Teixeira de Carvalho
- Moshe Arditi
- Michael C Fishbein
- Elizabeth A Jacobsen
- Youngho Lee
- Angela C Gomez
Institutions
- Universidade Estadual de Londrina (BR)
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Mayo Clinic in Arizona (US)
- Cedars-Sinai Smidt Heart Institute (US)
- Harvard Stem Cell Institute (US)
Publication Details
- Journal
- Clinical & Experimental Immunology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1093/cei/uxaf086
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Heart Association
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- National Institutes of Health